---
title: "SystImmune, a subsidiary of Baillie Gifford, triggers a $250 million milestone payment in collaboration with Bristol Myers Squibb"
description: "SystImmune, a wholly-owned subsidiary of BaiLi Tianheng, has reached an exclusive cooperation agreement with Bristol Myers Squibb regarding the iza-bren project. SystImmune has received an initial pay"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260783675.md"
published_at: "2025-10-12T09:40:03.000Z"
---

# SystImmune, a subsidiary of Baillie Gifford, triggers a $250 million milestone payment in collaboration with Bristol Myers Squibb

> SystImmune, a wholly-owned subsidiary of BaiLi Tianheng, has reached an exclusive cooperation agreement with Bristol Myers Squibb regarding the iza-bren project. SystImmune has received an initial payment of $800 million from BMS and triggered a milestone payment of $250 million. According to the agreement, SystImmune is also eligible for up to $7.1 billion in additional payments, the specific amount of which is subject to conditions and uncertainty

According to the Zhitong Finance APP, Baili Tianheng (688506.SH) announced that on December 11, 2023, its wholly-owned subsidiary SystImmune, Inc. (referred to as "SystImmune") reached an exclusive licensing and cooperation agreement with Bristol Myers Squibb (referred to as "BMS", NYSE code: BMY) regarding the iza-bren (BL-B01D1, EGFR×HER3 dual antibody ADC) project. As of March 7, 2024, the company has received an $800 million non-refundable and non-deductible upfront payment from BMS.

The global Phase II/III key registration clinical trial IZABRIGHT-Breast01 has achieved a milestone event, officially triggering the first $250 million near-term contingent payment under the cooperation agreement, and SystImmune will receive the payment shortly (the actual amount received will be subject to bank fees). According to the cooperation agreement, the company is also eligible for up to $250 million in additional near-term contingent payments, as well as up to $7.1 billion in additional payments upon reaching specific development, registration, and sales milestones. The milestone payments stipulated in the cooperation agreement are subject to certain conditions, and the final milestone payments remain uncertain

### Related Stocks

- [BMY.US - Bristol Myers Squibb](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Bristol Myers Squibb Releases Fourth Quarter and Full-Year 2025 Financial Results | Bristol-Myers Squibb Company has released its fourth quarter and full-year 2025 financial results. The earnings press re | [Link](https://longbridge.com/en/news/274966941.md) |
| Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell | Mubadala Investment Co PJSC has reported its shareholdings as of December 31, 2025. The company holds 444,978 shares in  | [Link](https://longbridge.com/en/news/276145564.md) |
| Bunker Hill Announces Amendment to $30 Million LIFE Offering of Units & Warrant Exercise | Bunker Hill Mining Corp. announced amendments to its $30 million LIFE Offering, involving approximately 138,900,000 unit | [Link](https://longbridge.com/en/news/275958604.md) |
| Ulusoy Un Says Cerealto Foods S.L. Notified That Ulusoy Un's Non-Binding Offer To Buy Cerealto Pasta Vb3, S.L.U Was Unsuccessful | Ulusoy Un Sanayi ve Ticaret AS :ULUSOY UN - CEREALTO FOODS S.L. NOTIFIED THAT ULUSOY UN'S NON-BINDING OFFER TO BUY CEREA | [Link](https://longbridge.com/en/news/275922310.md) |
| nVent Announces Quarterly Cash Dividend \| NVT Stock News | nVent Electric plc (NYSE: NVT) has declared a quarterly cash dividend of US$0.21 per ordinary share, payable on May 8, 2 | [Link](https://longbridge.com/en/news/276049666.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.